Dr. Philip Gold is the lead investigator for the following clinical trials currently available at the Swedish Cancer Institute:
Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. Clin Cancer Res. 2012 Feb 15;18(4):1092-1100. Epub 2011 Dec 16.
Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1;29(34):4555-60. Epub 2011 Oct 24.
El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2011 Jul 12.
Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ; NCI GI Steering Committee Colon Cancer Task Force. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist. 2011;16(8):1061-8. Epub 2011 Jul 7.
Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemotherapy Pharmacology. 2011 Dec;68(6):1595-602. Epub 2011 May 10.
Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, Blanke CD. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010 Sep;5(9):1472-6.
Iyengar T, Ramanathan RK, Gold PJ. What's causing this woman's chest pain? Gastroenterology. 2010 Jan;138(1):e1-2. Epub 2009 Nov 21.
Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009 Oct;27(5):469-75. Epub 2008 Oct 22.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006 Sep 1;24(25):4069-77.
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, et al. Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. J Clin Oncol 24:4914-4921, 2006.
Carlini LE, Meropol NJ, Bever D, Andria ML, Hill T, Gold P, et al. UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan. Clinical Cancer Research Vol. 11, 1226-1236, February 2005.
Masood, N., Gold, P.J, Thompson, J.A.. Paraneoplastic manifestations of renal cell carcinoma, in Renal and Adrenal Tumours - Biology and Management, Belldegrun, A., Figlin, R.A., Vaughn, E.D., Ritchie, A., and Oliver, T., eds. Oxford University Press, pp. 55-60, 2003.
Jacobs A, Gold P, et al: Interferon alpha-2a and 13-cis retinoic acid in patients with metastatic renal cell cancer. Cancer Invest 18(5):417-421, 2000.
Gold PJ, et all: Metastatic Renal Cell Carcinoma: Long term survival after therapy with high dose continuous infusion Interleukin-2. Cancer J Sci Am 3:S79-S84, 1997.
Thompson JA, Gold PJ, et al: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3:S79-S84, 1997.
Mankoff DA, Thompson JA, Gold PJ, et al: Identification of interleukin-2 (IL-2) induced complete response in metastatic renal call carcinoma by FDG PET despite radiographic evidence for persistent tumor: A case report. AJR 169:1049-1050, 1997.
Gold PJ, Thompson JA, Markowitz DR, Neumann S, Fefer A. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S85-91.
Lindgren CG, Thompson JA, Robinson N, Keeler T, Gold PJ, Fefer A. Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants. Bone Marrow Transplant. 1997 May;19(9):867-73.
Thompson JA, Gold PJ, Fefer A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol. 1997 Feb;24(1 Suppl 4):S44-8.
Gold PJ, Fefer A, Thompson J: Paraneoplastic Syndromes Associated with Renal Cell Carcinoma. Semin Urol Oncol. 14:216-222, 1996.
Gold PJ, Flowers MED, Sullivan KM: Outpatient Management of Marrow and Blood Stem Cell Recipients, in On Call in….Bone Marrow Transplantation, Burt KR, Deeg HJ, Lothian SC, Santos GW, Eds. R.G. Landes Co, Austin, Texas, 1996.
Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987 Dec;5 (12):1942-51.
ABSTRACTS AND PRESENTATIONS:
P. O. Bohanes, B. H. Goldman, L. P. Leichman, C. D. Blanke, S. Iqbal, C. R. Thomas, C. L. Corless, K. G. Billingsley, K. D. Danenberg, W. Zhang, J. K. Benedetti, P. J. Gold, H. Lenz. Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). J Clin Oncol 29: 2011 (suppl; abstr 4023) [Poster Discussion]
X. Zhu, P. J. Gold, A. B. El-Khoueiry, T. A. Abrams, H. Morikawa, T. Ohtomo, P. A. Philip. A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 29: 2011 (suppl; abstr 4085) [Poster Presentation]
Earhart RH, Rosen L, Mendelson D, Plaxe S, Gold P, et al. QTc study of picoplatin with emphasis on pharmacodynamics of cardiac repolarization. AACR-NCI-EORTC International Conference, ‘Molecular Targets and Cancer Therapeutics’, November 15-19, 2009, Boston, MA.
L. Leichman, B. H. Goldman, J. K. Benedetti, K. G. Billingsley, C. R. Thomas, S. Iqbal, H. Lenz, C. Blanke, P. J. Gold, C. L. Corless. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol 27:15s, 2009 (suppl; abstr 4513) [Poster Discussion]
J. Wu, F. Muggia, C. Henderson, L. Feun, P. V. Veldhuizen, P. Gold, H. Zheng, G. Abbadessa, J. Lewis, A. X. Zhu. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. J Clin Oncol 27, 2009 (suppl; abstr e15630)
Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group study. Proc ASCO 26:4536a, 2008. [Poster Discussion]
Gold PJ, Iriarte D, Arthur J, Kaplan H. Phase II trial of RAD001 in patients with refractory metastatic colorectal cancer. ASCO GI Cancer Symposium 2008. Abstract # 513. [Poster Presentation]
Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group study. ASCO GI Cancer Symposium 2008. Abstract # 96. [Poster Presentation]
Whitehead RP, McCoy S, Wollner IS, Gold PJ, Billingsley KG, Blanke CD. Phase II trial of depsipeptide (NCS-630176) in patients who have received either one or two prior chemotherapy regimens for metastatic of locally advanced, unresectable disease: A Southwest Oncology Group study. Proc ASCO 24:3598a, 2006. [Poster Presentation]
Gold PJ, Refice S, West H. Phase I trial of irinotedan and epirubicin in patients with advanced solid tumors. Proc ASCO 23:2120a, 2005.
Lenz HJ, Mayer RJ, Gold P, et al. Activity of Cetuximab in Patients with Colorectal Cancer Refractory to a Fluoropyrimidine, Irinotecan, and Oxalliplatin. ASCO GI Cancer Symposium 2005. Abstract # 10269.
Van Cutsem E, Mayer RJ, Gold P, et al. Correlation of acne skin rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer. 2004;85(supp 2):Abstract 279.
Carlini LE, Meropol NJ, Chen YM, McGarry C, Hill T, Gold P, Blanchard RL. Pharmacogenetic analysis of UGT1A1, UGT1A6, UGT1A7 and thymidylate synthase ina phse II study of capecitabine plus irinotecan in patients with metastatic colorectal cancer. Proc ASCO 23:3623a, 2004. [Poster Presentation]
Meropol NJ, Gold PJ, Diasio RB, et al. Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. Proc ASCO 23:3520a, 2004. [Poster Discussion]
Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc ASCO 23:3510a, 2004. [Poster Discussion]
Livingston RB, Edwards J, Gold PJ. Phase II trial of irinotecan and mitomycin C in the treatment of metastatic esophageal cancer. Proc ASCO 22:1171a, 2003. [Poster Presentation]
Gold PJ, Godfrey T, Khami M, et al. Capecitabine and irinotecan as first line therapy for patients with metastatic colorectal cancer: Phase II study preliminary results. Proc ASCO 22:1158a, 2003. [Poster Presentation]
Rinn K, Livingston R, Gold P: Phase II Trial of Irinotecan and Mitomycin in Patients with Metastatic Breast Cancer. Proc ASCO 21:2000a, 2002.
Gold P et al: Phase II Trial of Irinotecan and Mitomycin in Patients with Metastatic Colorectal Cancer. Proc ASCO 21:680a, 2002. [Poster Presentation]
Gold P et al: Phase II Trial of Irinotecan and Mitomycin in the Treatment of Metastatic Esophageal and Gastric Cancers. Proc ASCO 20:644a, 2001. [Poster Presentation]
Rinn K, Livingston R, Gold P: Phase II Trial of Irinotecan and Mitomycin in the Treatment of Metastatic Breast Cancer. Proc ASCO 20:1951a, 2001.
Gold P, Thompson J, Carter G, Livingston R: Phase II Trial of Irinotecan and Mitomycin C in the Treat¬ment of Metastatic Solid Tumors. Proc ASCO 19:839a, 2000.
Eary FJ, Mankoff DA, Thompson JA, Gold PJ, Krohn KA: Tumor Metabolism and Proliferation Using Quantitative PET Imaging in Renal Cell Carcinoma Patients Treated with IL-2. Proc ASCO 18:338a, 1999.
Jacobs AD, Dezso J, Ramirez C, Cain D, Gold PJ, Thompson J: Alpha-interferon and cis-retinoic acid in patients with metastatic renal cell cancer. Proc ASCO 16:1197a, 1997.
Gold PJ, Thompson JA, Lindgren C, et al: Phase I Trial of Subcutaneous, Outpatient Interleukin-2 for Patients with Advanced Mycosis Fungoides. Blood 88:191b, 1996.
Thompson J, Gold PJ, Fefer A: Outpatient Chemoimmunotherapy for Patients with Metastatic Melanoma. Proc ASCO 15:343a,1996.
Temple JD, Gold PJ, Mylvagnam R, Ahn YS, Harrington WJ: Danazol Therapy Decreases Mechanical Fragility of Normal and Sickle Erythrocytes. Blood 72:207a, 1988.
Kempin SJ, Gold PJ, et al: Hemostatic Alterations in Patients Receiving Recombinant Tumor Necrosis Factor. Blood 68:335a, 1986.
Kempin SJ, Gold PJ, et al: The Spectrum of Platelet and Coagulation Inhibitory Activity of Anti-Tumor Intercalating Agents. Blood 60:200a, 1982.
Kempin SJ, Gold PJ, et al: Selective and Irreversible Inhibition of Platelet Function by CS 216-942-A New Antitumor Agent. Blood 58:198a, 1981.
The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey.Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating.Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.